NEW YORK (GenomeWeb) — Asuragen said today that it has obtained CE marking for its new QuantideX next-generation sequencing oncology panel for the detection of clinically relevant variants.
The QuantideX NGS DNA Hotspot 21 kit is designed for use on the Illumina MiSeq platform and screens for 21 of the most commonly observed genomic variants across a variety of cancers including non-small cell lung cancer, colorectal cancer, and melanoma. It is available for research use only in the US.
Earlier this year, Asuragen announced expanded CE marking for its multiplexed QuantideX qPCR BCR-ABL IS kit and its QuantideX qPCR BCR-ABL minor kit.